Walder Wyss on the closing of Insmed strategic financing

Insmed Incorporated, a global biopharmaceutical company, closed a million strategic financing. The company has announced three strategic financings resulting in aggregate gross proceeds of USD 775 million. Proceeds from the transactions will strengthen Insmed’s financial position, which will place the Company in a position to deliver clinical data from each of its four pillars.

The financing includes a USD 350 million senior secured term loan with funds managed by Pharmakon Advisors, a leading investor in non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds and a USD 150 million secured royalty financing with OrbiMed, a leading investor in the healthcare industry.

Walder Wyss has advised the funds managed by Pharmakon Advisors, BioPharma Credit and OrbiMed. The team was led by Tervel Stoyanov (counsel, pictured) and further included associate Anaëlle Genoud and managing associate Valentin Wiesner, all banking & finance.